VANCOUVER, BC – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the… Read More
Marken announced the launch of Marken INsight, a service of our dynamic new partnership with TruLab, which revolutionizes sample management and tracking at the tube-level, with speed and proactivity for… Read More
VANCOUVER, BC – WAT Medical Enterprise achieves a major milestone: HeadaTerm 2 receives the OTC clearance from the U.S. Food and Drug Administration (FDA), making it one of the only… Read More
VANCOUVER, BC – WAT Medical Enterprise achieves a major milestone: HeadaTerm 2 receives the OTC clearance from the U.S. Food and Drug Administration (FDA), making it one of the only wearable… Read More
45 mg once daily oral dose selected for Phase 3 Results support trial expansion to lower age group and study will now include adolescents ages 10-17 years If positive, pre-planned… Read More
